Dr. Savant specializes in the treatment of comorbid psychiatric disorders in medically ill patients.

She is a double board certified in Psychosomatic Medicine and General Psychiatry.

Dr. Savant is involved in helping develop an electronic medical record focused on making mental health more trackable and to potentially use the collected data in predicting episodes of mental illness.

Clinical Focus

  • Psychiatry

Academic Appointments

  • Clinical Assistant Professor, Psychiatry and Behavioral Sciences

Honors & Awards

  • Achievement Award, Loyola University Medical Center Department of Psychiatry
  • Medical Honor Society, Alpha Omega Alpha Medical Honor Society

Boards, Advisory Committees, Professional Organizations

  • Co-Founder and Chief Medical Officer, Savant Care Inc. (2014 - Present)
  • Board Certified in Psychiatry, American Board of Psychiatry and Neurology (2013 - Present)
  • Board Certified in Psychosomatic Medicine, American Board of Psychiatry and Neurology (2015 - Present)

Professional Education

  • Board Certification: Psychiatry, American Board of Psychiatry and Neurology (2013)
  • Board Certification: Psychosomatic Medicine, American Board of Psychiatry and Neurology (2015)
  • Medical Education:Government Med College-Punjab (2008) India
  • Fellowship:Stanford Univ Medical Center (2014) CA
  • Residency:Loyola Univ Of Chicago Stritch (2013) IL
  • Internship:Rajendra Hospital And Med Coll (2008) India
  • MD, Stanford Hospitals and Clinics, Psychosomatic Medicine (Fellowship) (2014)
  • MD, Loyola University Medical Center, Adult Psychiatry (Residency) (2013)

Current Research and Scholarly Interests

Neural networks and AI for behavioral health applications


  • Development and deployment of neural networks and artificial intelligence for predicting and tracking of behavioral health, Savant Care Inc. (2014 - Present)

    Artificial intelligence is the future. Through the use of a robust EMR integrated with an advance neural network, the SCBrain AI is able to parse data and make smart decisions and recommendations to providers based on patients' diagnosis, life events, medications, etc... From self-learning, the AI is also able to predict risks and associations between certain risk factors or behavioral changes which may produce or be indicative of an onset of a behavioral health crisis or event.


    4966 El Camino Real #224, Los Altos, CA 94022


    • Sonia Parikh, MD, Savant Care Inc.

    For More Information:

All Publications

  • A Study of the Psychometric Properties of the "Stanford Proxy Test for Delirium" (S-PTD): ANew Screening Tool for the DetectionofDelirium. Psychosomatics Maldonado, J. R., Sher, Y. I., Benitez-Lopez, M. A., Savant, V., Garcia, R., Ament, A., De Guzman, E. 2019


    BACKGROUND: Delirium is a prevalent neuropsychiatric disorder associated with increased morbidity and mortality. Half the cases remain misdiagnosed.OBJECTIVE: Assess the effectiveness of the Stanford Proxy Test for Delirium (S-PTD) in detecting delirium in an inpatient setting.METHODS: This is a comparison study. Daily assessment with S-PTD, by the patient's nurse, and a neuropsychiatric assessment by a psychiatrist. Assessments were blinded. Inclusion criteria included 18 years or older. Exclusion criteria included patient's or surrogate's unwillingness to participate, inability to consent if a surrogate was not available, and inability to communicate in English or Spanish. A total of 309 patients were approached: 27 declined participation, 4 were excluded, and 278 subjects were followed up throughout their hospital stay. In the end, 78 were excluded for lack of neuropsychiatric assessment, S-PTD, or both. One was excluded for lack of demographic data. The sensitivity and specificity of the S-PTD in detecting delirium when compared with a neuropsychiatric assessment.RESULTS: Participants were on average 60.8 years old and 54.3% were male. Patients who developed delirium were, on average, older (15.12 y, confidence interval: 8.94-21.32). A total of 199 patients were analyzed; 43 patients (21.6%) met criteria for delirium. S-PTD detected 67 days with delirium (16.5%) of 405 hospital days, while neuropsychiatric evaluation identified 83 (20.5%). S-PTD had a sensitivity of 80.72% and a specificity of 90.37%.CONCLUSION: S-PTD is an effective, comprehensive, and simple screening tool for delirium, which is robust despite fluctuating symptoms and lack of cooperation. The use of S-PTD may enhance early diagnosis of delirium.

    View details for DOI 10.1016/j.psym.2019.11.009

    View details for PubMedID 31926650